DYRK1B and ovarian carcinoma: Compared with Mirk expression in most of ovarian cancer specimens, it was weakly expressed only in about 37% ovarian cystadenomas (Fig. 5C) and not expressed in the ovarian non-neoplastic cysts (Fig. 5D), indicating Mirk may be associated with ovarian tumorigenesis.